Maik J. Grundeken

A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial

Patrick W. Serruys, Bernard Chevalier, Dariusz Dudek et al. · The Lancet · 2014 · 560 citations · Full text

Medicine, Cardiology, Surgery +17

Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry

Robin P. Kraak, Mariëlla E.C.J. Hassell, Maik J. Grundeken et al. · EuroIntervention · 2015 · 131 citations · Full text

Medicine, Cardiology, Surgery +17

A Randomized Trial of a Dedicated Bifurcation Stent Versus Provisional Stenting in the Treatment of Coronary Bifurcation Lesions

Philippe Généreux, Indulis Kumsārs, Maciej Lesiak et al. · Journal of the American College of Cardiology · 2015 · 116 citations · Full text

Medicine, Cardiology, Surgery +14

Distal Embolization of Hydrophilic-Coating Material From Coronary Guidewires After Percutaneous Coronary Interventions

Maik J. Grundeken, Xiaofei Li, C. Eline Kurpershoek et al. · Circulation Cardiovascular Interventions · 2015 · 70 citations · Full text

Medicine, Cardiology, Surgery +16

Founder mutations in the Netherlands

Pieter G. Postema, Maarten P. van den Berg, J. Peter van Tintelen et al. · Netherlands Heart Journal · 2009 · 63 citations · Full text

Life Sciences, Genetics, Molecular Genetics +8